When was EnGeneIC founded?

EnGeneIC was founded in 2000 and raised its 1st funding round 11 years after it was founded.

Where is EnGeneIC located?

EnGeneIC is headquartered in Lane Cove, Australia.

Who is the current CEO of EnGeneIC?

Jennifer MacDiarmid of EnGeneIC.

How many employees does EnGeneIC have?

As of Sep 30, 2026, the latest employee count at EnGeneIC is 61.

Is EnGeneIC a funded company?

EnGeneIC is a funded company, having raised a total of $25.1M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 27, 2011.

When was the latest funding round of EnGeneIC?

EnGeneIC's latest funding was a $***** Series B round on Apr 04, 2017, with participation from 0 investor.

Where does EnGeneIC rank among its competitors?

EnGeneIC ranks 711th amongst 3790 active competitors, of which 1194 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of EnGeneIC?

EnGeneIC's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

EnGeneIC - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of targeted anti-cancer therapies using nanocell platform technology. The company focuses on research, development, and manufacturing. It utilizes a proprietary nanocell platform for targeted delivery of chemotherapeutics and functional nucleic acids. The technology aims to target tumors directly and leverage the patient’s own immune system.

Website: engeneic.com
Social
Email ID: *****@engeneic.com

Key Metrics

Founded Year

2000

Location

Lane Cove, Australia

Stage

Series B

Total Funding

$25.1M in 5 rounds

Latest Funding Round

Series B, Apr 04, 2017, $*****

Investors

GRT Capital Partners & 5 more

Ranked

711^th among 3790 active competitors

Employee Count

61 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3436 more

View EnGeneIC's full profile

EnGeneIC has raised a total funding of $25.1M over 5 rounds. Its first funding round was on Jul 27, 2011. EnGeneIC has 6 institutional investors.

Here is the list of recent funding rounds of EnGeneIC:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 04, 2017	6690799	Series B	6503045	4072558	5945449	6443939
Jul 24, 2015	5698702	Series B	4867579	7023036	1092203	8721065
Dec 12, 2014	1668597	Series B	4573581	9358878	GRT Capital Partners	Foley Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of EnGeneIC's funding rounds and investors

The founders of EnGeneIC is Jennifer MacDiarmid.

Here are the details of EnGeneIC's key team members:

Jennifer MacDiarmid: Co-Founder, Joint CEO & Director of EnGeneIC.
Contact Info: 1 email address

View details of EnGeneIC's Founder profiles and Board Members

EnGeneIC's employee count trend

EnGeneIC has 61 employees as of Sep 26. Here is EnGeneIC's employee count trend over the years:

Uncover EnGeneIC's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EnGeneIC include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of EnGeneIC, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
711th	EnGeneIC 2000, Lane Cove (Australia), Series B	Developer of targeted anti-cancer therapies using nanocell platform technology	$25.1M	CHAMP Ventures, Foley Ventures & 4 others	47/100